HK1172269A1 - Pharmaceutical composition for treatment of dry eye syndrome - Google Patents

Pharmaceutical composition for treatment of dry eye syndrome

Info

Publication number: HK1172269A1
Authority: HK; Hong Kong
Prior art keywords: treatment; pharmaceutical composition; dry eye; eye syndrome; syndrome
Prior art date: 2009-12-14

Application number

HK12113225.6A

Other languages

English (en)

Chinese (zh)

Inventor

巴斯蒂安．泰辛格

索尼婭．泰辛格

伯爾哈德．岡瑟

Original Assignee

諾瓦利克有限責任公司

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-12-14

Filing date

2012-12-20

Publication date

2013-04-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41731659&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1172269(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-12-20 Application filed by 諾瓦利克有限責任公司 filed Critical 諾瓦利克有限責任公司

2013-04-19 Publication of HK1172269A1 publication Critical patent/HK1172269A1/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Oil, Petroleum & Natural Gas (AREA)
Ophthalmology & Optometry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Transplantation (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

HK12113225.6A 2009-12-14 2012-12-20 Pharmaceutical composition for treatment of dry eye syndrome HK1172269A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP09015423A EP2335735A1 (en)	2009-12-14	2009-12-14	Pharmaceutical composition for treatment of dry eye syndrome
PCT/EP2010/069495 WO2011073134A1 (en)	2009-12-14	2010-12-13	Pharmaceutical composition for treatment of dry eye syndrome

Publications (1)

Publication Number	Publication Date
HK1172269A1 true HK1172269A1 (en)	2013-04-19

Family

ID=41731659

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HK12113225.6A HK1172269A1 (en)	2009-12-14	2012-12-20	Pharmaceutical composition for treatment of dry eye syndrome

Country Status (16)

Country	Link
US (1)	US8614178B2 (pt)
EP (2)	EP2335735A1 (pt)
JP (5)	JP5663595B2 (pt)
KR (2)	KR101652714B1 (pt)
CN (1)	CN102652022B (pt)
AU (1)	AU2010333039B2 (pt)
BR (3)	BR112012014190B8 (pt)
CA (2)	CA2941956C (pt)
DK (1)	DK2512515T3 (pt)
ES (1)	ES2449308T3 (pt)
HK (1)	HK1172269A1 (pt)
IN (1)	IN2012DN03128A (pt)
MX (1)	MX2012006720A (pt)
PL (1)	PL2512515T3 (pt)
PT (1)	PT2512515E (pt)
WO (1)	WO2011073134A1 (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2437684B1 (en)	2009-06-03	2022-06-15	ForSight Vision5, Inc.	Anterior segment drug delivery
CN102869345B (zh)	2010-03-17	2015-02-11	诺瓦利克有限责任公司	用于治疗眼内压增高的药物组合物
EP2444063A1 (en)	2010-10-20	2012-04-25	Novaliq GmbH	Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en)	2010-11-11	2012-06-13	Novaliq GmbH	Liquid pharmaceutical compositions for the treatment of a posterior eye disease
CA2834862C (en)	2011-05-25	2019-12-17	Novaliq Gmbh	Pharmaceutical composition for administration to nails
CA2834855C (en)	2011-05-25	2020-12-29	Novaliq Gmbh	Topical pharmaceutical composition based on semifluorinated alkanes
JP6084987B2 (ja)	2012-01-23	2017-02-22	ノバリックゲーエムベーハー	セミフッ素化アルカンに基づく安定化タンパク質組成物
CA2883002C (en) *	2012-09-12	2019-05-21	Novaliq Gmbh	Compositions comprising mixtures of semifluorinated alkanes
PL2708228T3 (pl)	2012-09-12	2018-11-30	Novaliq Gmbh	Kompozycje do przemywania oczu
ES2745084T3 (es)	2012-09-12	2020-02-27	Novaliq Gmbh	Composiciones de alcanos semifluorados para uso en el tratamiento de la queraconjuntivitis seca
EP2730291A1 (en) *	2012-11-09	2014-05-14	Fluoron Gmbh	Internal Tamponade Composition
CA2899206C (en)	2013-01-24	2019-07-09	Transderm, Inc.	Compositions for transdermal delivery of mtor inhibitors
JP6304475B2 (ja) *	2013-01-31	2018-04-04	ロート製薬株式会社	点眼剤
EP3689348A1 (en) *	2013-03-13	2020-08-05	Santen Pharmaceutical Co., Ltd.	Therapeutic agent for meibomian gland dysfunction
KR102272568B1 (ko) *	2013-07-23	2021-07-05	노바리크 게엠베하	안정화 항체 조성물
US20160243291A1 (en) *	2013-10-15	2016-08-25	Forsight Vision5, Inc.	Formulations and Methods for Increasing or Reducing Mucus
US20200237859A1 (en)	2019-01-25	2020-07-30	Newport Research, Inc.	Aqueous suspensions of cyclosporin
US11324800B2 (en)	2015-01-15	2022-05-10	Wellspring Ophthalmics, Inc.	Aqueous suspensions of cyclosporin
WO2016168141A1 (en)	2015-04-13	2016-10-20	Forsight Vision5, Inc.	Ocular insert composition of semi-crystalline or crystalline pharmaceutically active agent
WO2017058774A1 (en) *	2015-09-29	2017-04-06	The Regents Of The University Of California	Methods of diagnosing diseases of mucosal surfaces
DK3356313T3 (da) *	2015-09-30	2020-07-20	Novaliq Gmbh	2-perfluorhexyloktan til oftalmisk indgivelse
CN108348777B (zh)	2015-09-30	2020-04-28	诺瓦利克有限责任公司	半氟化化合物和其组合物
KR102257916B1 (ko)	2016-06-23	2021-05-28	노바리크 게엠베하	드롭 디스펜서를 포함하는 키트
AU2017329772B2 (en) *	2016-09-22	2023-02-02	Novaliq Gmbh	Pharmaceutical compositions for use in the therapy of blepharitis
MX2019003364A (es) *	2016-09-23	2019-10-02	Novaliq Gmbh	Composiciones oftalmicas que comprenden ciclosporina.
JP2019534867A (ja) *	2016-09-28	2019-12-05	ノバリックゲーエムベーハー	カンナビノイド受容体結合リガンドを含む組成物
MX2019007586A (es) *	2016-12-22	2019-12-11	Novaliq Gmbh	Composiciones que comprenden tacrolimus para el tratamiento de enfermedades inflamatorias intraoculares.
MX2019007587A (es) *	2016-12-23	2019-12-16	Novaliq Gmbh	Composicion oftalmica para el tratamiento de la enfermedad del ojo seco.
AU2018205253B2 (en)	2017-01-06	2022-01-13	Palvella Therapeutics, Inc.	Anhydrous compositions of mTOR inhibitors and methods of use
EP3612228B1 (en)	2017-04-21	2023-08-23	Dermaliq Therapeutics, Inc.	Iodine compositions
EP3619186B1 (en)	2017-05-05	2021-02-17	Novaliq GmbH	Process for the production of semifluorinated alkanes
US11278503B2 (en)	2017-05-12	2022-03-22	Novaliq Gmbh	Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
EP3687496A1 (en)	2017-09-27	2020-08-05	Novaliq GmbH	Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases
US11896559B2 (en)	2017-10-04	2024-02-13	Novaliq Gmbh	Opthalmic compositions comprising F6H8
WO2019166631A1 (en)	2018-03-02	2019-09-06	Novaliq Gmbh	Pharmaceutical compositions comprising nebivolol
EP3817743A4 (en)	2018-07-02	2022-07-06	Palvella Therapeutics, Inc.	ANHYDROUS COMPOSITIONS OF MTOR INHIBITORS AND METHODS OF USE
WO2020058504A1 (en)	2018-09-22	2020-03-26	Novaliq Gmbh	Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness
CA3112504A1 (en)	2018-09-27	2020-04-02	Novaliq Gmbh	Lipid barrier repair
SG11202102820VA (en)	2018-10-12	2021-04-29	Novaliq Gmbh	Ophthalmic composition for treatment of dry eye disease
CN113518619A (zh) *	2019-01-21	2021-10-19	诺瓦利克有限责任公司	用于治疗眼部新生血管形成的药物组合物
AU2020281641A1 (en)	2019-05-24	2022-01-27	Novaliq Gmbh	Ophthalmic composition for the treatment of ocular allergy
AU2020340561A1 (en)	2019-09-06	2022-03-31	Novaliq Gmbh	Ophthalmic composition for the treatment of uveitis
WO2021048803A1 (en)	2019-09-13	2021-03-18	Minas Coroneo	Eye drop dispenser
WO2021191273A1 (en)	2020-03-24	2021-09-30	Hovione Scientia Limited	Compositions for use in treating meibomian gland dysfunction
WO2024170514A1 (en) *	2023-02-13	2024-08-22	Novaliq Gmbh	Ophthalmic composition for ocular surgery preparation in patients with ocular surface disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0667850B2 (ja)	1987-09-03	1994-08-31	ユニバーシティオブジョージアリサーチファウンデーション，インコーポレイテッド	眼科用サイクロスポリン組成物
US4839342A (en)	1987-09-03	1989-06-13	University Of Georgia Research Foundation, Inc.	Method of increasing tear production by topical administration of cyclosporin
US5874481A (en) *	1995-06-07	1999-02-23	Alliance Pharmaceutical Corp.	Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
DE19536504C2 (de) *	1995-09-29	1999-09-23	H Meinert	Verwendung fluorierter Alkane
DE19861012A1 (de) *	1998-03-18	1999-09-30	Pharm Pur Gmbh	Behandlungsmittel für die Ophthalmologie
PT1173177E (pt) *	1999-04-30	2005-03-31	Sucampo A G	Utilizacao de compostos macrolidos para tratamento do olho seco
DE19938668B4 (de) *	1999-08-14	2006-01-26	Bausch & Lomb Inc.	Tränenersatzmittel
US20030018044A1 (en) *	2000-02-18	2003-01-23	Peyman Gholam A.	Treatment of ocular disease
WO2005099718A1 (en) *	2004-04-19	2005-10-27	Centre National De La Recherche Scientifique (C.N.R.S.)	Lung surfactant supplements
JP2008501806A (ja) *	2004-06-08	2008-01-24	オキュラリスファーマ，インコーポレイテッド	疎水性眼用組成物および使用方法
DE102007055046A1 (de) *	2007-11-19	2009-05-28	Fluoron Gmbh	Infusionslösung
ATE532505T1 (de)	2008-04-18	2011-11-15	Novaliq Gmbh	Inhalative und instillative verwendung von semifluorierten alkanen als wirkstoffträger im intrapulmonalen bereich

2009
- 2009-12-14 EP EP09015423A patent/EP2335735A1/en not_active Withdrawn
2010
- 2010-12-13 AU AU2010333039A patent/AU2010333039B2/en active Active
- 2010-12-13 IN IN3128DEN2012 patent/IN2012DN03128A/en unknown
- 2010-12-13 CA CA2941956A patent/CA2941956C/en active Active
- 2010-12-13 BR BR112012014190A patent/BR112012014190B8/pt active IP Right Grant
- 2010-12-13 KR KR1020127018066A patent/KR101652714B1/ko active IP Right Grant
- 2010-12-13 WO PCT/EP2010/069495 patent/WO2011073134A1/en active Application Filing
- 2010-12-13 US US13/513,886 patent/US8614178B2/en active Active
- 2010-12-13 BR BR122020020872-4A patent/BR122020020872B1/pt active IP Right Grant
- 2010-12-13 PT PT107907750T patent/PT2512515E/pt unknown
- 2010-12-13 CA CA2776860A patent/CA2776860C/en active Active
- 2010-12-13 KR KR1020167023214A patent/KR101722039B1/ko active IP Right Review Request
- 2010-12-13 DK DK10790775.0T patent/DK2512515T3/en active
- 2010-12-13 MX MX2012006720A patent/MX2012006720A/es active IP Right Grant
- 2010-12-13 BR BR122017018955-7A patent/BR122017018955B1/pt active IP Right Grant
- 2010-12-13 PL PL10790775T patent/PL2512515T3/pl unknown
- 2010-12-13 JP JP2012542577A patent/JP5663595B2/ja active Active
- 2010-12-13 EP EP10790775.0A patent/EP2512515B1/en active Active
- 2010-12-13 ES ES10790775.0T patent/ES2449308T3/es active Active
- 2010-12-13 CN CN201080055507.7A patent/CN102652022B/zh active Active
2012
- 2012-12-20 HK HK12113225.6A patent/HK1172269A1/xx unknown
2014
- 2014-10-01 JP JP2014203406A patent/JP6096731B2/ja active Active
2016
- 2016-12-22 JP JP2016248533A patent/JP6397472B2/ja active Active
2018
- 2018-08-31 JP JP2018163569A patent/JP2019006803A/ja active Pending
- 2018-12-28 JP JP2018248700A patent/JP6731039B2/ja active Active

Also Published As

Publication number	Publication date
CA2776860A1 (en)	2011-06-23
BR122020020872B1 (pt)	2021-09-08
JP2013513586A (ja)	2013-04-22
EP2512515A1 (en)	2012-10-24
JP2015028064A (ja)	2015-02-12
CN102652022A (zh)	2012-08-29
CA2941956C (en)	2018-09-04
BR112012014190B8 (pt)	2021-05-25
PT2512515E (pt)	2014-03-04
BR112012014190A2 (pt)	2016-05-31
AU2010333039B2 (en)	2014-08-28
CA2776860C (en)	2016-10-25
JP2017078086A (ja)	2017-04-27
EP2335735A1 (en)	2011-06-22
JP2019070003A (ja)	2019-05-09
MX2012006720A (es)	2012-07-30
JP2019006803A (ja)	2019-01-17
PL2512515T3 (pl)	2014-05-30
KR101722039B1 (ko)	2017-03-31
JP5663595B2 (ja)	2015-02-04
CA2941956A1 (en)	2011-06-23
BR112012014190B1 (pt)	2021-03-02
US20120244177A1 (en)	2012-09-27
JP6731039B2 (ja)	2020-07-29
JP6096731B2 (ja)	2017-03-15
EP2512515B1 (en)	2013-12-25
AU2010333039A1 (en)	2012-07-12
KR20160105533A (ko)	2016-09-06
DK2512515T3 (en)	2014-03-10
ES2449308T3 (es)	2014-03-19
KR101652714B1 (ko)	2016-09-01
JP6397472B2 (ja)	2018-09-26
WO2011073134A1 (en)	2011-06-23
US8614178B2 (en)	2013-12-24
CN102652022B (zh)	2014-12-17
KR20120115977A (ko)	2012-10-19
IN2012DN03128A (pt)	2015-09-18
BR122017018955B1 (pt)	2022-03-08

Publication	Publication Date	Title
HK1172269A1 (en)	2013-04-19	Pharmaceutical composition for treatment of dry eye syndrome
IL216800A (en)	2017-03-30	Preparation for the treatment of dry eye syndrome
HK1175398A1 (en)	2013-07-05	Pharmaceutical composition for treatment of increased intraocular pressure
EP2554175A4 (en)	2013-08-21	COMPOSITION FOR THE TREATMENT OF A DESIRED PART
PT2482812T (pt)	2023-01-24	Composições farmacêuticas compreendendo bi-1356 e metformina
HK1170490A1 (zh)	2013-03-01	用於青光眼的治療或預防的醫藥組合物
HK1217287A1 (zh)	2017-01-06	活性物質的凍干組合物
HK1141447A1 (en)	2010-11-12	Pharmaceutical composition for the treatment of proliferative diseases
PT2429507T (pt)	2017-10-30	Composição farmacêutica isenta de fosfatos para o tratamento do glaucoma
GB0902040D0 (en)	2009-03-11	Composition for treatment of skin
IL231622B (en)	2018-10-31	A pharmaceutical preparation for the treatment of stubbornness
EP2213303A4 (en)	2011-12-28	PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CATARACT
EP2465512A4 (en)	2013-02-20	PHARMACEUTICAL COMPOSITION FOR PREVENTING PAIN
ZA201104670B (en)	2012-03-28	Pharmaceutical composition comprising aleglitazar
HK1188791A1 (zh)	2014-05-16	新型八氫噻吩並喹啉衍生物、包含所述衍生物的藥物組合物及它們的用途
HK1155659A1 (en)	2012-05-25	Pharmaceutical composition for treatment of fibromyalgia
PL2604264T3 (pl)	2015-03-31	Kompozycja farmaceutyczna do leczenia chorób wirusowych
IL218726A0 (en)	2012-06-28	Methods and pharmaceutical compositions for treating down syndrome
IL200753A (en)	2015-06-30	Pharmaceutical preparation containing ib – meca for the treatment of psoriasis
ZA201204341B (en)	2013-08-28	Pharmaceutical composition for treating gutaneous burns
EP2402342A4 (en)	2012-09-19	PHARMACEUTICAL COMPOSITION FOR TREATING TYPE 2 DIABETES
IL215854A0 (en)	2012-01-31	Pharmaceutical compositions for the treatment of nasal polyposis
ZA201200531B (en)	2012-10-31	Pharmaceutical composition of rifampicin
HUP1100534A2 (en)	2013-04-29	Pharmaceutical composition for the treatment of muscle atrophy
IL219050A0 (en)	2012-06-28	Pharmaceutical composition for the treatment of bladder disorders